Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease

Trial Profile

A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latiglutenase (Primary)
  • Indications Coeliac disease
  • Focus Therapeutic Use
  • Sponsors ImmunogenX
  • Most Recent Events

    • 08 Aug 2019 According to an ImmunogenX media release, David M. Maahs MD, PhD of Stanford is the co-principle investigator of the "fast-track" project (benefit of doubt given since this information is about the project).
    • 08 Aug 2019 According to an ImmunogenX media release, this trial will be conducted at the Stanford University School of Medicine in the Department of Pediatrics and Joseph A. Murray MD of the Mayo Clinic and Jack A. Syage PhD of ImmunogenX are the co-principle investigators of the project.
    • 09 Apr 2019 According to a National Institutes of Health media release, the co-Principle investigators for this study are Joseph A. Murray MD of the Mayo Clinic and Jack A. Syage PhD of ImmunogenX.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top